BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lipoxen (LPX.L)'s Bio-Polymer Technology Granted Important US Patent


1/14/2010 11:10:51 AM

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces today that it has been granted a new US patent for its PolyXen technology. This technology is based on polysialic acid (PSA), (a polymer occurring naturally in humans) which extends a protein’s active life, is biodegradable, non-immunogenic and non-toxic, and which is also therefore expected to avoid the toxicity attributed to polyethylene glycol in PEGylated protein drug candidates.

Polysialylation of therapeutic proteins i.e. the attachment of PSA on these molecules, is often hampered by random attachment of PSA molecules onto the protein. As a result, attached PSA can mask the active site of the therapeutic. In many cases, masking of activity can lead to complete loss of the protein's therapeutic function.

To avoid such problems, polysialylation is targeted on a specific domain on the protein, away from the active site. To that end, a specific domain is created by the introduction of a cysteine on the protein molecule (away from the active site) through protein engineering.

The US granted patent refers to the preparation of the PSA-linker-SH (cysteine)-protein construct. It has been shown that a number of therapeutic proteins which have been polysialylated, retain most of their activity as well as all the advantages of polysialylation i.e. improved drug performance and longer circulation time of the drug in the body.

In summary, the patent identifies that polysialylation, Lipoxen's PolyXen platform, is more effective in improving the therapeutic function of protein drugs.

Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: “The new patent grant on this natural polymer which extends the active life of protein enhances our patent position in the world’s largest pharmaceutical market and further supports our drive to become a leading innovator within the next generation biologic drug space.

Lipoxen has two potential billion dollar block-buster products in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO) both of which are based on this PolyXen technology. We are confident that this new patent will strengthen our commercial position as well as our capability to collaborate with partners.”


Read at BioSpace.com

Lipoxen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES